Ironwood Pharmaceuticals, Inc.
Simbolis: IRWD
NASDAQ
6.74
USDRinkos kaina šiandien
-1.0492
P/E santykis
0.1032
PEG koeficientas
1.07B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Ironwood Pharmaceuticals, Inc. (IRWD) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 92.2 | 656.2 | 620.1 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 129.1 | 115.5 | 114 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 1.3 | 1.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 12 | 7.7 | 9.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 233.3 | 780.6 | 745.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 18.2 | 20.3 | 22.9 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 3.7 | 0 | 0 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3.7 | -15.1 | -24.5 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 212.3 | 283.7 | 333.3 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 3.6 | 15.9 | 25.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 237.8 | 319.9 | 381.7 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 7.8 | 0.5 | 0.9 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 202.7 | 3.1 | 120 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 1.2 | 0.7 | 0.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 498.3 | 412.9 | 355.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 64.3 | 22 | 1.3 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 541.3 | 422.6 | 359.3 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 14.5 | 19.7 | 21.6 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 817.4 | 448.1 | 521 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -1698.6 | -696.4 | -937.6 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -3 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1355.2 | 1348.6 | 1543.4 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 471.1 | 1100.5 | 1126.9 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | -346.3 | 652.4 | 605.9 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 0 | 15.1 | 24.5 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 715.5 | 415.9 | 475.8 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 623.4 | -240.3 | -144.3 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -1002.2 | 175.1 | 528.4 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 72.6 | 65.7 | -333.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 32 | 27 | 22.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 11.3 | 2.8 | 17.7 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 0.9 | 8 | 7.7 | |||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 12.4 | -8.1 | -2.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -2 | 2.9 | 12.7 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 1068.2 | 1.7 | 25.2 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1026 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1026.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -300 | -120.7 | 0 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 6.4 | 9.5 | 19.6 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -126.4 | -24.1 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -111.2 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 570.8 | 111.2 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 277.2 | -237.6 | -4.5 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -0.1 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -565.3 | 36.1 | 257.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 92.2 | 657.9 | 621.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 657.5 | 621.9 | 364.8 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 183.4 | 273.8 | 261.9 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -0.3 | -0.1 | -0.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 183.2 | 273.6 | 261.6 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 442.7 | 410.6 | 413.8 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 1.6 | 1.4 | 1.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 441.2 | 409.2 | 412.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 232.1 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 233.7 | 160.3 | 181.5 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 19 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -1157.1 | 2.1 | -31.6 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 21.6 | 7.6 | 31.1 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1.6 | 9.5 | 0.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 209 | 250.3 | 232.3 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -948.1 | 252.4 | 200.7 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 83.5 | 77.4 | -327.8 | |||||||||||||||||
income-statement-row.row.net-income | 0 | -1002.2 | 175.1 | 528.4 |
Dažnai užduodami klausimai
Kas yra Ironwood Pharmaceuticals, Inc. (IRWD) bendras turtas?
Ironwood Pharmaceuticals, Inc. (IRWD) bendras turtas yra 471073000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.996.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 1.174.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -2.264.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -2.120.
Kas yra Ironwood Pharmaceuticals, Inc. (IRWD) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -1002239000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 715538000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 232124000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.